These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 22161222)

  • 1. Design of pharmacokinetic studies for latent covariates.
    Lagishetty CV; Coulter CV; Duffull SB
    J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):87-97. PubMed ID: 22161222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A reduction in between subject variability is not mandatory for selecting a new covariate.
    Lagishetty CV; Vajjah P; Duffull SB
    J Pharmacokinet Pharmacodyn; 2012 Aug; 39(4):383-92. PubMed ID: 22767340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model.
    Ribbing J; Jonsson EN
    J Pharmacokinet Pharmacodyn; 2004 Apr; 31(2):109-34. PubMed ID: 15379381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How large are the consequences of covariate imbalance in cluster randomized trials: a simulation study with a continuous outcome and a binary covariate at the cluster level.
    Moerbeek M; van Schie S
    BMC Med Res Methodol; 2016 Jul; 16():79. PubMed ID: 27401771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The lasso--a novel method for predictive covariate model building in nonlinear mixed effects models.
    Ribbing J; Nyberg J; Caster O; Jonsson EN
    J Pharmacokinet Pharmacodyn; 2007 Aug; 34(4):485-517. PubMed ID: 17516152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A fast method for testing covariates in population PK/PD Models.
    Khandelwal A; Harling K; Jonsson EN; Hooker AC; Karlsson MO
    AAPS J; 2011 Sep; 13(3):464-72. PubMed ID: 21725709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of correlation on covariate selection in linear and nonlinear mixed effect models.
    Bonate PL
    Pharm Stat; 2017 Jan; 16(1):45-54. PubMed ID: 27580760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjusted adaptive Lasso for covariate model-building in nonlinear mixed-effect pharmacokinetic models.
    Haem E; Harling K; Ayatollahi SM; Zare N; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2017 Feb; 44(1):55-66. PubMed ID: 28144841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data.
    Tunblad K; Lindbom L; McFadyen L; Jonsson EN; Marshall S; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2008 Oct; 35(5):503-26. PubMed ID: 19011957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of type I error rates when modeling ordered categorical data in NONMEM.
    Wählby U; Matolcsi K; Karlsson MO; Jonsson EN
    J Pharmacokinet Pharmacodyn; 2004 Feb; 31(1):61-74. PubMed ID: 15346852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of misspecification of residual error or correlation structure on the type I error rate for covariate inclusion.
    Silber HE; Kjellsson MC; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2009 Feb; 36(1):81-99. PubMed ID: 19219538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Evolutionary Search Algorithm for Covariate Models in Population Pharmacokinetic Analysis.
    Yamashita F; Fujita A; Sasa Y; Higuchi Y; Tsuda M; Hashida M
    J Pharm Sci; 2017 Sep; 106(9):2407-2411. PubMed ID: 28450239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testing for marginal covariate effect when the subgroup size induced by the covariate is informative.
    Anyaso-Samuel S; Datta S
    Stat Methods Med Res; 2024 Jul; 33(7):1264-1277. PubMed ID: 38767219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further Evaluation of Covariate Analysis using Empirical Bayes Estimates in Population Pharmacokinetics: the Perception of Shrinkage and Likelihood Ratio Test.
    Xu XS; Yuan M; Yang H; Feng Y; Xu J; Pinheiro J
    AAPS J; 2017 Jan; 19(1):264-273. PubMed ID: 27761720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Operating characteristics of stepwise covariate selection in pharmacometric modeling.
    Ahamadi M; Largajolli A; Diderichsen PM; de Greef R; Kerbusch T; Witjes H; Chawla A; Davis CB; Gheyas F
    J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):273-285. PubMed ID: 31020450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of actual significance levels for covariate effects in NONMEM.
    Wählby U; Jonsson EN; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2001 Jun; 28(3):231-52. PubMed ID: 11468939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of treatment with a continuous variable: simulation study of significance level for several methods of analysis.
    Royston P; Sauerbrei W
    Stat Med; 2013 Sep; 32(22):3788-803. PubMed ID: 23580422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007.
    McLeay SC; Morrish GA; Kirkpatrick CM; Green B
    Clin Pharmacokinet; 2012 May; 51(5):319-30. PubMed ID: 22439649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm.
    Bertrand J; Comets E; Laffont CM; Chenel M; Mentré F
    J Pharmacokinet Pharmacodyn; 2009 Aug; 36(4):317-39. PubMed ID: 19562469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating tests for cluster-randomized trials with few clusters under generalized linear mixed models with covariate adjustment: A simulation study.
    Qiu H; Cook AJ; Bobb JF
    Stat Med; 2024 Jan; 43(2):201-215. PubMed ID: 37933766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.